Our proposed research will be focused on two objectives: The first is to fill existing gaps in the immunogenetic analysis of the HLA-D system and to reach a more detailed knowledge of the polymorphism of DR, DQ and DR subregions. This study will be done at the protein level by the immunochemical approach we have developed. The second is to investigate the role that different Class II products play in the generation of HLA-associated diseases. By radioimmunoassay typing, several newly discovered markers, located on different Class II molecules, will be tested for their association with coeliac disease, insulin-dependent diabetes mellitus and rheumatoid arthritis. For the coeliac disease, an analysis at the DNA level will be performed with he aim of defining the precise disease-associated sequence site. Specifically, we will direct our effort toward the following projects: 1) Analysis of HLA Class II molecules controlled by different DR haplotypes and of those expressed on mouse cells transfected with a single DR Beta gene by immunospecifically isolating the Class II molecules and analyzing their structural features by two-dimensional peptide mapping. 2) Subunit assignment of DQ alloantigenic determinants by serologically analyzing the Class II molecules expressed on mouse cells transfected either with DQw2 Alpha and DQw3 Beta genes or with DQw2 Beta and DQw3 Alpha genes. 3) Serological detection of HLA-DP allospecificity by isolating DP molecules from mouse cells transfected with DP Alpha and Beta genes and testing their reactivity with anti-Class II alloantisera by the direct binding assay. 4) HLA-disease association studies by typing patients with coeliac disease, insulin-dependent diabetes mellitus and rheumatoid arthritis for newly found """"""""haplotype-discriminating specificities"""""""". 5) Molecular genetic study of coeliac disease by sequencing the Beta domain of DQw2 molecules expressed on cells of B-cell lines established from DR3-homozygous coeliac disease patients by using the primer extension method.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI020251-06
Application #
3129806
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1983-07-01
Project End
1990-08-31
Budget Start
1988-09-01
Budget End
1990-08-31
Support Year
6
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Sorrentino, R; Iannicola, C; Costanzi, S et al. (1990) Arg74 in HLA-DRB1 and DRB3 controls a DR3-related epitope. Immunogenetics 32:8-12
Sorrentino, R; Iannicola, C; Botti, S et al. (1989) DNA typing of an HLA-DR bilocus specificity by gene amplification and oligonucleotide hybridization. Immunogenetics 29:225-30
Pistillo, M P; Tanigaki, N; Chua, R et al. (1989) Human anti-HLA-DQw2 monoclonal antibody secreted by an Epstein-Barr-virus--transformed lymphoblastoid cell line: assessment of the monoclonality, allospecificity, and target. Hum Immunol 24:253-63
Colonna, M; Tanigaki, N; Tosi, R et al. (1989) Serological detection and molecular localization of allelic HLA-DP supertypic epitopes. Eur J Immunol 19:433-40
Mazzoleni, O; Longo, A; Angelini, G et al. (1989) Human monoclonal antibody MP8 detects a supertypic determinant encoded by DPB alleles DPB2.1, DPB3, DPB4.2, DPB8, DPB9, DPB10, and DPB14. Immunogenetics 30:502-5
Berte, C C; Tanigaki, N; Tosi, R et al. (1988) Serological recognition of HLA-DR allodeterminant corresponding to DNA sequence involved in gene conversion. Immunogenetics 27:167-73
Ameglio, F; Benedetto, A; Marotta, P et al. (1988) A high proportion of sera of heroin addicts possesses anti-HLA class I and class II reactivity. Clin Immunol Immunopathol 46:328-34
Pistillo, M P; Mazzoleni, O; Tanigaki, N et al. (1988) Human anti-HLA monoclonal antibodies: production, characterization, and application. Hum Immunol 21:265-78
Tanigaki, N; Tosi, R; Strominger, J L et al. (1987) Immunochemistry of the HLA class II molecules isolated from a mouse cell transfected with DQ alpha and beta genes from a DR4 haplotype. Immunogenetics 26:40-7
Pistillo, M P; Tanigaki, N; Mazzoleni, O et al. (1987) Human lymphoblastoid cell lines secreting antibodies with restricted HLA specificity. Immunogenetics 25:145-51

Showing the most recent 10 out of 21 publications